Arctiin and its aglucone, arctigenin from the fruits of Arctium lappa L. showed potent in vitro antiviral activities against influenza A virus (A/NWS/33, H1N1) (IFV). Based on the data from time-of-addition experiments and on release tests of progeny viruses, arctigenin was assumed to interfere with early event(s) of viral replication after viral penetration into cells, and to suppress the release of progeny viruses from the host cells. Arctiin was orally effective against either IFV-inoculated normal or 5-fluorouracil (5-FU)-treated mice, being less effective as compared with oseltamivir. Noticeably, arctiin produced a larger amount of virus-specific antibody than those of control and oseltamivir in sera collected from 5-FU-treated mice. Furthermore, oral treatment of 5-FU-treated mice with arctiin did not induce any resistant viruses, although the same treatment with oseltamivir induced resistant viruses at a 50% frequency. When the combination of arctiin and oseltamivir was administered to normal mice infected with IFV, the virus yields in both bronchoalveolar lavage fluids and lungs were significantly reduced relative to those in the mice treated with arctiin or oseltamivir alone. Thus, monotherapy of arctiin or combined therapy of arctiin with oseltamivir would be another treatment option for influenza.
A neuramidase inhibitor, oseltamivir (Tamiflu) is now being stockpiled by many countries in preparation for human-to-human transmission of highly pathogenic avian influenza. However, oseltamivir-resistant influenza viruses, as well as abnormal behavior occurring in the patients receiving oseltamivir, [1] [2] [3] have emerged as serious global-scale problems. According to a recent release by the Ministry of Health, Labour and Welfare of Japan in 2009, olsetamivirresistant influenza A virus Soviet Union type was detected in 97.1% of patients infected with this type of virus in 11 prefectures of Japan. Although orally inhalable zanamivir (Relenza), another neuraminidase inhibitor, is currently used as a substitute for oseltamivir for patients infected with oseltamivir-resistant viruses, the concern over its central nervous system (CNS) side effects for teenagers has been growing. Should widespread outbreaks of oseltamivir-resistant influenza occur, many people may die before a vaccine against this pathogen becomes available. Thus, we need more options for the treatment of influenza by developing new type anti-flu drugs which reduce the severity of influenza.
During a course of exploratory investigations on antiviral constituents from natural sources, we found out that two lignan constituents: arctiin and its aglucone, arctigenin, from the fruits of Arctium lappa L. (Japanese name "goboshi") [4] [5] [6] [7] [8] have potent inhibitory effects on the replication of influenza A virus (A/NWS/33, H1N1) (IFV). Anti-influenza virus activity of arctigenin was previously reported by the group of G. Yang, who found that arctigenin showed directly in vitro inhibitory effect against influenza virus replication and was an active constituent of Fructus arctii for relieving exterior syndrome.
9) The prolonged effect of intranasal treatment of arctigenin on the survival time of influenza-infected mice was demonstrated by the group of Z. Yang. 10) However, little information is available about the pharmacological property of this compound. In the present study, we examined an in vitro anti-IFV profile of arctigenin under different experimental conditions. In addition, in vivo experiments were performed to evaluate the efficacy of arctiin in immunocompetent and immunocompromised animals infected with IFV. The combinational effects of these compounds in combination with oseltamivir were also studied in in vitro and in vivo systems.
MATERIALS AND METHODS

Materials and Instruments
Eagle's minimal essential medium (MEM) was obtained from Nissui Pharmaceutical Co., Ltd. (Tokyo, Japan). Oseltamivir phosphate was purchased from Chugai Pharmaceutical Co., Ltd. (Tokyo, Japan). Other chemicals were obtained from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). Electrospray ionization (ESI)-MS was recorded on an API 3000 mass spectrometer (Applied Biosystems). The 1 H-and 13 C-NMR spectra were measured in chloroform-d on a JEOL EX-400 (400, 100 MHz, respectively) using tetramethylsilane as an internal standard. IR was recorded on KBr using Shimadzu FT-IR-8400 infrared spectrophotometer.
Cell and Virus Madin-Darby canine kidney epithelial (MDCK) cells and influenza A virus (A/NWS/33, H1N1) were obtained from Denka Seiken Co., Ltd. (Niigata, Japan). The cells were grown in MEM supplemented with 5% fetal bovine serum (FBS), and the virus propagated in MDCK cells.
Animals Female BALB/c mice were obtained from Japan SLC (Shizuoka, Japan). All animal experiments were conducted in accordance with the animal experimentation guidelines of the University of Toyama with the approval of the Animal Care Committee at the University of Toyama. No observable side effects such as diarrhea due to drug administration were detected throughout the experiments.
Isolation of Arctiin and Arctigenin The dry fruit powder (500 g) of Arctium lappa L. purchased from Tochimoto Tenkaido Co., Ltd. (Osaka, Japan) was treated successively with n-hexane, ether and chloroform according to the previously reported procedure.
11) The chloroform extract was chromatographed over SiO 2 with chloroform : MeOH (95 : 5) as an eluent, yielding arctiin (9.9 g) as a white powder. An aliquot (100 mg) of arctiin was suspended in 0.2 N H 2 SO 4 (15 ml) and heated at 80°C under stirring for 1 h. The reaction mixture was concentrated to give a crude product, which was purified by PLC with CHCl 3 
Antiviral Activity and Cytotoxicity
For cell growth inhibition studies, MDCK cells were cultured for 72 h in the presence of increasing amounts of arctiin or arctigenin. Viable cell yield was determined by the trypan blue exclusion test. The inhibition data were plotted as dose-response curves, from which the 50% cell growth inhibitory concentration (CC 50 ) was obtained. In the antiviral assays, the plaque yield reduction assay was employed as described previously. 12, 13) Briefly, MDCK cell monolayers in 48-well plates were infected with IFV at 0.1 plaque-forming unit (PFU) per cell at room temperature. After 1 h of viral infection, the monolayers were washed three times with phosphate-buffered saline (PBS) and incubated at 37°C. Samples were added during infection and throughout the incubation thereafter (A) or immediately after virus infection (B). Virus yields were determined by plaque assay after 1 d of incubation. The antiviral activity was expressed as the 50% inhibitory concentration (IC 50 ), which was the sample concentration that reduced plaque numbers by 50% in the treated cultures as compared with no drug controls. Antiviral activities were estimated by selectivity indices (SIs) calculated from CC 50 and IC 50 values.
Time-of-Addition Experiments MDCK cell monolayers were infected with IFV at 0.5 PFU per cell. Arctigenin (final concentrations of 5 or 25 mM) or oseltamivir (final concentrations of 1 mM) was administered 3 h before viral infection, during infection for 1 h, during infection and throughout the incubation thereafter, immediately after infection, at 2 h post infection (p.i.), at 4 h p.i., at 6 h p.i., or at 8 h p.i. At 20 h p.i., the cell cultures were harvested and subjected to plaque assay.
Virus Adsorption Assay The effect of arctigenin on virus adsorption to host cells was assayed by an infectious center assay. 14) IFV (1 PFU/cell), MDCK cell monolayers and arctigenin were cooled on ice for 3 h before mixing at 4°C. After incubation of MDCK cell monolayers with IFV and arctigenin (final concentrations of 5, 25, 50 mM) at 4°C for 1 h, the cells were washed with ice-cold PBS to remove unbound viruses and free compound. After trypsinization of the cells, the cell pellets were diluted 100-and 1000-fold with ice-cold PBS and immediately added to MDCK cell monolayers in 12-well plates to be plaque assayed.
Virus Penetration Assay Virus penetration into host cells was evaluated according to the method reported by Huang and Wagner 15) with some modifications. MDCK cell monolayers in 24-well plates precooled on ice for 2 h were infected with IFV (approximately 100 PFU/well) at 4°C for 1 h in the absence of compound. After washing with ice-cold PBS, the cell monolayers were incubated with arctigenin (final concentrations of 0, 5, 25, 50 mM) at 37°C. At 0, 0.5, 1, 2 and 3 h after temperature shift to 37°C, the cell monolayers were treated with 40 mM citrate buffer (pH 3.0) for 1 min to inactivate unpenetrated viruses and overlaid with agar medium to be plaque assayed.
Assay for Virus Release MDCK cell monolayers were infected with IFV at 0.1 PFU/cell. After adsorption at room temperature for 1 h, the monolayers were washed three times with PBS and incubated at 37°C. After 30 min incubation, the cells were treated with citrate buffer to inactivate unpenetrated viruses, and cultured in fresh medium containing 5 mM of arctigenin. After 24 h p.i., the medium and infected cells were harvested separately to be subjected to plaque assay.
In Vitro Interaction between Arctigenin and Oseltamivir After infection of MDCK cells with IFV at 0.1 PFU per cell, each compound at concentrations below IC 50 was added to the cell cultures. At 1 d of incubation at 37°C, the cell cultures were subjected to plaque assay. The interaction between arctigenin and oseltamivir was evaluated by isobologram method 16) in which the x and y axes showed the ratio of the concentrations of arctigenin and IC 50 of arctigenin, and 50% fractional inhibitory concentrations (FIC 50 s) of oseltamivir, respectively.
Time-Course Analysis of Plasma Concentrations of Arctiin and Arctigenin Blood was collected from the carotid artery of BALB/c mice (6-7 weeks old, nϭ3) and centrifuged at 3000 rpm at 25°C for 10 min to separate blood plasmas. Arctiin (1.07 mg) and arctigenin (0.74 mg) were separately added to a mixture of blood plasma (200 ml) and CH 3 CN (800 ml), which was successively stirred on vortex and centrifuged at 13500 rpm at 4°C for 5 min, to give super-natants. An aliquot (50 ml) of the supernatant was diluted with CH 3 CN to the concentrations of 10, 5 and 2.5 mM of arctiin or arctigenin. An aliquot (5 ml) of the solution was subjected to HPLC-ESI-MS measurements using an Agilent 1100 series HPLC system (Yokogawa Analytical Systems) (Inertsil ® ODS-3, GL Sciences: 3 mm, 2.1 mm i.d.ϫ50 mm) connected with an mass spectrometer (positive mode). The mobile phase was a CH 3 CN/water containing 0.1% formic acid solution; flow rate, 0.4 ml/min; detection, 254 nm with the following gradient system: 0-15 min, 20-80% CH 3 CN; 15-18 min, 80-100% CH 3 CN; 18-24 min, 100% CH 3 CN; 24-26 min, 100-20% CH 3 CN; 26-30 min, 20% CH 3 CN. The HPLC peaks at t R 7 min (arctiin) and 8 min (arctigenin) gave a base ion peak at m/z: 373 arising from [arctigeninϩH] ϩ , respectively. MS/MS measurements of this peak provided a daughter ion peak at m/z: 173 as a base peak, which was monitored by a selected reaction monitoring technique (SRM), and its peak area was measured to prepare a calibration curve.
Arctiin (5.0 mg/ml in 1% ethanol) was orally administered to BALB/c mice (6-7 weeks old), and blood samples were collected from the carotid artery of mice after 0.5, 1, 3, 6, 12 and 24 h (nϭ3 each). The blood samples were centrifuged at 3000 rpm for 10 min to separate the blood plasmas. An aliquot (50 ml) was diluted with CH 3 CN (200 ml), stirred on vortex and centrifuged at 13500 rpm at 4°C for 5 min to give the supernatant. An aliquot (5 ml) of the supernatant was subjected to ESI-MS/MS in the same way as described above. The peak areas at m/z: 173 were measured by SRM, and plasma concentrations of arctiin and arctigenin were calculated using the corresponding calibration curves mentioned above.
Animal Experiments Mice were intranasally infected with 2ϫ10 5 PFU of virus in 50 ml PBS at day 0. Arctiin and oseltamivir were given by oral administration at a dose of 5 mg/d and 0.2 mg/d, respectively, twice a day from 0 to 7 d after virus inoculation by beginning at 30 min after virus infection. In half of the mice, 5-fluorouracil (5-FU) was injected subcutaneously every other day at a dose of 0.5 mg per treatment from 7 d before virus inoculation to 13 d after inoculation. Blood and lung samples, and bronchoalveolar lavage fluids (BALFs) were collected from each group at 3 and 7 d. Blood samples were centrifuged at 3000 rpm for 10 min, and sera were stored at Ϫ20°C. Lung samples were sonicated for 10 s after the addition of 1 ml of PBS per mg of lung tissue and centrifuged at 10000 rpm for 30 min to separate the supernatants, which were then stored at Ϫ80°C. BALF samples were prepared by four washes with 0.8 ml of ice-cold PBS via a tracheal cannula and centrifuged at 1500 rpm for 10 min to obtain the supernatants, which were then stored at Ϫ80°C. Virus titers in these samples were determined by plaque assay on MDCK cell monolayers. In another experiment, to mice infected with IFV (2ϫ10 6 PFU/mouse) were orally administered arctiin (1 mg/d) alone, oseltamivir (0.02, 0.05 or 0.2 mg/d) alone, or a combination of arctiin and oseltamivir twice a day for 3 d after virus inoculation. The virus yields of the lung and BALF samples from these mice were determined at 3 d post-inoculation.
Assay for Neutralizing Antibody Neutralizing anti-IFV antibody titers were determined using 50% plaque reduction assay. Serum samples at 5-to 78125-fold dilutions (0.1 ml)
were mixed with approximately 200 PFU of virus (0.1 ml) and incubated at 37°C for 1 h. Each mixture was added onto MDCK cell monolayers in 35-mm dishes to measure the residual virus infectivity by plaque assay. The neutralizing antibody titer was defined as the highest dilution of the serum that reduced the plaque numbers by 50% compared with control without serum.
Assay of Drug Resistance The lung and BALF samples were collected from 5-FU-injected mice that were treated with arctiin or oseltamivir for 7 d after virus inoculation. From each sample, 48 viruses were recovered by plaque purification. Drug susceptibility of these isolates was evaluated by plaque assay in the presence of increasing concentrations of arctiin or oseltamivir, and compared with the challenge virus without drug treatment.
Statistical Analysis A comparison between the two groups was made using the Student's t test.
RESULTS
Antiviral Activity
Anti-IFV activities of arctiin and arctigenin were examined by the plaque yield reduction assay. The two compounds exerted anti-IFV activities as judged from their selectivity indices being greater than 12 (Table 1) .
Since these compounds showed similar IC 50 values when added either during infection (A) or immediately after virus infection (B), it was presumed that they would interact with stage(s) of viral replication after viral attachment to host cells. Arctigenin had 6-to 8-fold lower IC 50 s than those of arctiin, while showing 6-fold higher cytotoxicity than arctiin. In order to characterize the antiviral action of arctigenin, its effects on in vitro IFV replication were studied in detail as described below.
Effect of Time-of-Addition of Arctigenin on IFV Infectivity To delineate the drug-sensitive phases of IFV replication to arctigenin, time-of-addition experiments were conducted. As shown in Table 2 , while arctigenin exerted no marked effects when added before and during viral infection, the compound concentration-dependently reduced the IFV titers when added after infection. Less potent inhibition of viral replication was observed when arctigenin was added at 2 h p.i. as compared with that obtained by its addition immediately after infection. On the other hand, oseltamivir showed similar inhibitory effects when added from 0, 2, 4, 6 and 8 h p.i.
Effect of Arctigenin on Virus Adsorption and Penetration
The results of time-of-reaction experiments suggested that the sensitive stage(s) of IFV replication to arctigenin might be early events after virus attachment into host cells. Thus, the inhibitory effects of arctigenin on virus adsorption and penetration were examined according to the reported methods. 17, 18) The compound did not interfere with virus attachment to host cells at the concentrations of 5, 25 and 50 mM (data not shown). The compound showed weak effects against the virus penetration in a concentration-dependent manner (Table 3) .
Effect of Arctigenin on the Release of Progeny Viruses The IFV replication was suppressed, though not strongly, even after late (8 h p.i.) addition of arctigenin to cell cultures (Table 2) , the release process of progeny viruses might be another possible target of the compound. Thus, the effect of arctigenin on virus release from infected cells was further evaluated. The compound reduced released viruses at around its IC 50 in a time-dependent manner (Fig. 1) .
In Vitro Combined Effects of Arctigenin and Oseltamivir on IFV Replication Since the results mentioned so far strongly suggested that arctigenin and oseltamivir might have different targets of IFV replication from each other, we examined whether or not the synergistic effects of their combination might be observed in antiviral activity. IFV-infected MDCK cells were incubated in the medium supplemented with arctiin and/or oseltamivir at different concentrations less than their IC 50 s. Arciin decreased the IC 50 of oseltamivir even at concentrations below those required for anti-IFV activity. As shown in the isoblogram (Fig. 2) , where displacement of the curve to the left indicates synergistic interaction between arctigenin and oseltamivir, anti-IFV synergism was observed between the two compounds.
Time-Course of Plasma Concentrations of Arctiin and Arctigenin in Mice
The blood samples of mice were obtained at 0.5-12 h after oral administration of arctiin and subjected to the determination of the concentrations of arctiin and its metabolite. Figure 3 showed that arctiin was hydrolyzed to arctigenin immediately after administration, and was present in the blood for over 12 h. It was therefore con- a) The number of viruses penetrated at 3 h p.i. in no-drug control was taken as 100%. Each value is the mean from triplicate assays.
Fig. 1. Effect of Arctigenin on Virus Release from IFV-Infected Cells
MDCK cells were infected with IFV at 0.1 PFU/cell, and arctigenin (5 mM) was added to the medium at 30 min p.i. for 24 h. The supernatants were determined for virus release.
a The number of released viruses at 24 h p.i. in no-drug control was taken as 100%. Each value is the mean from triplicate assays.
Fig. 2. In Vitro Interaction between Arctigenin and Oseltamivir
Different concentrations of oseltamivir were combined with the concentrations of arctigenin for the determination of antiviral activity. The x axis is the ratio of the fixed concentration of arctigenin to the concentration of arctigenin that produced 50% inhibition of virus replication (IC 50 ) in the absence of oseltamivir. The y axis is the fractional inhibitory concentration (FIC) of oseltamivir that is the ratio of the IC 50 of oseltamivir in the presence of a fixed concentration of arctigenin to the IC 50 of oseltamivir in the absence of arctigenin. The broken line shows the theoretical plot for independent inhibitors. Each value is the mean from duplicate assays.
Fig. 3. Time-Course Plasma Concentrations of Arctiin and Arctigenin
Arctiin (5.0 mg/ml in 1% ethanol) was orally administered to mice, and the blood was collected over 24 h. Blood samples were treated as described in Materials and Methods. Plasma concentrations of arctiin and arctigenin were determined by a SRM technique in mass spectrometry. Each value is the meanϮS.D. from triplicate determinations.
cluded that administration of arctiin twice a day might be adequate.
Effects of Arctiin on Changes in Body Weight and Mortality of IFV-Infected Mice Arctiin (5 mg/d) or oseltamivir (0.2 mg/d) was orally administered after viral infection to the 5-FU-immunocompromised (5-FU(ϩ)) or immunocompetent (5-FU(Ϫ)) mice. 5-FU(Ϫ) and 5-FU(ϩ) mice of control groups showed approximately 30% reduction of body weight at 7 and 9 d after infection, respectively (data not shown). The body weight of 5-FU(Ϫ) mice treated with oseltamivir showed only 7% reduction at 3 d after infection and recovered gradually thereafter, whereas 5-FU(ϩ) mice administered with oseltamivir exhibited a constant reduction of body weight even after the acute phase of infection. 5-FU(Ϫ) mice administered with arctiin showed only 13% reduction in body weight at day 7, suggesting the protective effect of arctiin on influenza infection.
In 5-FU(Ϫ) and 5-FU(ϩ) control groups, higher mortality rates of 36.4% and 72.7%, respectively, were observed during 6 to 10 d after infection (Table 4 ). The mortalities of arctiin-administered 5-FU(Ϫ) and 5-FU(ϩ) mice were reduced to approximately halves (20.0, 40.0%, respectively) as compared with those of control groups. These results indicated that oral arctiin protected mice from lethal infection with IFV, although the compound was less effective than oseltamivir.
Effects of Arctiin on Virus Replication in Mice
Arctiin reduced the virus yields in the lungs and BALFs of 5-FU(Ϫ) mice at 3 d p.i. to 55% ( pϽ0.01) and 44% (pϽ0.01) of controls, respectively, but no significant reduction in the virus titers was observed in 5-FU(ϩ) mice administered with arctiin (data not shown). At 7 d p.i. when no virus was detected in 5-FU(Ϫ) groups, however, arctiin reduced the virus production in the lung and BALF samples of 5-FU(ϩ) mice to 37% ( pϽ0.01) (Fig. 4A) and 16% ( pϽ0.01) (Fig. 4B) of controls, respectively. These rates were greater than the values [12% (pϽ0.01) and 1% ( pϽ0.01) in the lung and BALF samples, respectively] obtained from 5-FU(ϩ) mice fed with oseltamivir (Figs. 4A, B) . Figure 5 shows the effects of arctiin and oseltamivir on the systemic antibody response to IFV. At 3 d p.i., there was no significant difference in neutralizing antibody titers among all groups, ranging from 31 to 39. At 7 d p.i., antibody titers in the sera were markedly increased in the 5-FU(Ϫ) mice of all the groups. The antibody titer in the mice treated with arctiin, though smaller than the titer of control, was much higher than that in the mice treated with oseltamivir. The antibody titers in the 5-FU(ϩ) mice were not so high as those in the 5-FU(Ϫ) mice. However, it should be noted that arctiin produced a relatively higher antibody titer (1800Ϯ670) (pϽ0.05) than those of oseltamivir (170Ϯ74) (pϽ0.01) and control (990Ϯ490) at 7 d p.i.
Effects of Arctiin on Antibody Responses in Sera and Mucosa
Antibody titers were under the detection limit in the BALFs of 5-FU(Ϫ) mice at 3 d p.i. and of 5-FU(ϩ) mice at 3 and 7 d p.i. in all groups (data not shown). The 5-FU(Ϫ) mice treated with arctiin at 7 d p.i. showed slightly higher mucosal antibody titers (21.3Ϯ11.4) than those of the control (7.7Ϯ9.7) and oseltamivir-treated mice (2.6Ϯ0.43) (data not shown).
Drug Susceptibility of Virus Isolates from IFV-Infected Mice Virus isolates were obtained by plaque purification from the BALF and lung samples of 5-FU(ϩ) mice at 7 d p.i., and their susceptibility to the corresponding drugs was evaluated based on the IC 50 values. In arctiin treated mice, there were no marked changes in the susceptibility of these isolates to arctiin as compared with that of the challenge virus, the range of the IC 50 s being within that of the challenge virus (Table 5 ). On the other hand, oseltamivir produced a subpopulation of drug-resistant viruses in both the lung and BALF samples from immunosuppressed mice. That is, 24 of 48 isolates showed more than 10-fold reduction in Table 4 In Vivo Combined Effects of Arctiin and Oseltamivir on IFV Infection Arctiin and oseltamivir were orally administered alone or in combination to mice two times a day for 3 d after virus inoculation. Figure 6 shows the virus yields of the BALFs and lungs collected at 3 d p.i. from the mice. In the BALF samples, the combinations of arctiin (1 mg/d) and oseltamivir (0.02, 0.05 or 0.2 mg/d) reduced significantly the virus titers to 21% (pϽ0.001), 29% (pϽ0.01) and 60% (pϽ0.01) of those obtained from mice treated with oseltamivir alone, respectively. In the lung samples, the combinations of arctiin (1 mg/d) and lower doses (0.02, 0.05 mg/d) of oseltamivir reduced the virus titers to 61% (pϽ0.001) and 64% (pϽ0.01, respectively, compared to oseltamivir alone, while no potentiated antiviral effect was observed for the combination of arctiin and a high dose (0.2 mg/d) of oseltamivir.
DISCUSSION
Arctigenin had potent in vitro anti-IFV activities, which were approximately 6-to 8-fold lower than those of arctiin. In the mice, arctiin was metabolized to give arctigenin (Fig.   3 ). Thus, arctigenin might be deduced to be the active agent in the cells. Furthermore, the combinational incubation of arctigenin and oseltamivir represented the synergistic reduction of virus yields in an in vitro assay system (Fig. 2) . These results prompted us to investigate anti-IFV profile of arctiin and arctigenin through both in vitro and in vivo tests. To estimate sensitive phases to arctigenin in the IFV replication, the time-of-addition test was conducted (Table 2) . When arctigenin was administered to MDCK cell cultures at different times of virus infection, the compound most potently inhibited virus replication by its addition immediately after viral infection, but was less effective when added at 2 h p.i. or later. On the other hand, oseltamivir inhibited the virus replication to a similar extent when added during a period of 0-8 h after infection, suggesting a different mode of action from that of arctigenin. These results suggested that arctigenin might interact with early stage(s) of viral replication after virus penetration such as the uncoating of the viruses and trafficking of ribonucleoprotein complexes into the nucleus that might occur within 2 h after virus infection. 19) In accordance with this suggestion, the step of virus adsorption to host cells was not inhibited even at high concentrations (25, 50 mM) of arctigenin. Virus penetration into host cells, a step that occurred just after virus adsorption, was not inhibited by arctigenin at around its IC 50 (Table 3) . The results obtained so far suggested that arctigenin interferes with early intracellular events after virus penetration into the host cells, which might contribute at least in part to the inhibition of virus release. Considering the facts that the IFV replication was suppressed, though to a small extent, even after the late (8 h p.i.) addition of arctigenin, it is not ruled out that arctigenin would interfere with the release step of progeny viruses as well. The antiviral mechanism of this compound should be figured out in more detail.
Arctiin and oseltamivir were orally administered separately to IFV-infected 5-FU(ϩ) or 5-FU(Ϫ) mice in the time schedules as specified. Their therapeutic efficacies on IFV-infected 5-FU(ϩ) or 5-FU(Ϫ) mice were compared based on the body weight change, survival rate, virus yields in lungs and BALFs as well as neutralizing antibody titers in sera and BALFs. 5-FU is an anticancer drug with immunosuppressive 1204 Vol. 33, No. 7 action. 20, 21) In the present study, the 5-FU-treated mice mimicked an immunosuppressed state like that caused by aging, stress or medical treatments such as cancer chemotherapy and organ transplantation. Arctiin did not recover the body weight of mice. However, the mortalities were decreased to about halves as compared with those of control mice by the treatment with arctiin (Table 4) . When the extents of virus loads in IFV-infected mice were examined, arctiin did not reduce the virus yields of the lung and BALF as much as oseltamivir did in either 5-FU-treated or untreated mice at 3 d p.i. At 7 d p.i., however, not only oseltamivir but also arctiin significantly decreased the virus titers of both lung and BALF of 5(FU(ϩ)) mice (Fig. 4) . In sera, arctiin induced a much higher neutralizing antibody titer than did oseltamivir and control in 5-FU-treated mice (Fig. 5) . This tendency was also the case in the BALFs of the 5-FU-untreated mice, though to a lesser extent, suggesting that arctiin might be a promising candidate as a therapeutic agent against influenza.
Drug-resistant influenza viruses have emerged with increased frequency especially in children and immunocompromised patients. 22, 23) In support of this finding, in the present study, virus variants with drug resistance were recovered at a ratio of 50% from the immunosuppressed mice treated with oseltamivir. Surprisingly, no isolates with decreased sensitivity to arctiin were detected among the clones collected from the 5-FU(ϩ)-mice fed with arctiin (Table 5) .
Based on the in vitro combinational antiviral test (Fig. 2) , it was expected that co-adiministration of arctiin with oseltamivir to mice might have in vivo synergistic therapeutic efficacy. In our experiments, co-administration of arctiin and oseltamivir reduced significantly the virus production in mice relative to the titers for administration of each alone (Fig. 6) . Especially, the combinations of arctiin (1 mg/d) and oseltamivir (0.02 or 0.05 mg/d) synergistically reduced the virus titers in the BALF samples. Thus, combination therapy with these compounds could decrease the advent of the CNS side effects and drug-resistant virus variants, and thus prolong the useful life of oseltamivir.
In conclusion, arctiin and arctigenin from Arctium lappa L. have a potent profile as an influenza therapeutic agent, involving the protection from lethal IFV-infection, inhibition of viral replication, increased immune response, low frequency of drug resistant virus generation and increased antiviral efficacy with oseltamivir. The stability of these compounds was proved because they could be detected for a longer time, over 12 h, in the blood of mice administered orally with arctiin. Thus, arctiin and arctigenin may offer new options for treatment of influenza.
